» Articles » PMID: 35486871

Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions That Promotes Disease Persistence

Abstract

The dynamics describing the vicious cycle characteristic of cystic fibrosis (CF) lung disease, initiated by stagnant mucus and perpetuated by infection and inflammation, remain unclear. Here we determine the effect of the CF airway milieu, with persistent mucoobstruction, resident pathogens, and inflammation, on the mucin quantity and quality that govern lung disease pathogenesis and progression. The concentrations of MUC5AC and MUC5B were measured and characterized in sputum samples from subjects with CF ( = 44) and healthy subjects ( = 29) with respect to their macromolecular properties, degree of proteolysis, and glycomics diversity. These parameters were related to quantitative microbiome and clinical data. MUC5AC and MUC5B concentrations were elevated, 30- and 8-fold, respectively, in CF as compared with control sputum. Mucin parameters did not correlate with hypertonic saline, inhaled corticosteroids, or antibiotics use. No differences in mucin parameters were detected at baseline versus during exacerbations. Mucin concentrations significantly correlated with the age and sputum human neutrophil elastase activity. Although significantly more proteolytic cleavages were detected in CF mucins, their macromolecular properties (e.g., size and molecular weight) were not significantly different than control mucins, likely reflecting the role of bonds in maintaining multimeric structures. No evidence of giant mucin macromolecule reflecting oxidative stress-induced cross-linking was found. Mucin glycomic analysis revealed significantly more sialylated glycans in CF, and the total abundance of nonsulfated O-glycans correlated with the relative abundance of pathogens. Collectively, the interaction of mucins, pathogens, epithelium, and inflammatory cells promotes proteomic and glycomic changes that reflect a persistent mucoobstructive, infectious, and inflammatory state.

Citing Articles

Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.

Maloney Norcross S, Levin L, Hickey A, Hill D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770469 PMC: 11728674. DOI: 10.3390/ph17121628.


Rheological comparison of sputum and reconstituted airway epithelium mucus.

Esteban Enjuto L, Taty Poaty V, Bouveret M, Song H, Constant S, Patarin J Sci Rep. 2024; 14(1):31660.

PMID: 39738355 PMC: 11685952. DOI: 10.1038/s41598-024-80932-y.


Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target.

Mall M, Davies J, Donaldson S, Jain R, Chalmers J, Shteinberg M Eur Respir Rev. 2024; 33(173).

PMID: 39293854 PMC: 11409056. DOI: 10.1183/16000617.0001-2024.


Iron content of commercial mucin contributes to compositional stability of a cystic fibrosis airway synthetic microbiota community.

Giedraitis E, Neve R, Phelan V bioRxiv. 2024; .

PMID: 39282275 PMC: 11398496. DOI: 10.1101/2024.09.06.611695.


Cystic fibrosis.

Mall M, Burgel P, Castellani C, Davies J, Salathe M, Taylor-Cousar J Nat Rev Dis Primers. 2024; 10(1):53.

PMID: 39117676 DOI: 10.1038/s41572-024-00538-6.


References
1.
Hill D, Vasquez P, Mellnik J, McKinley S, Vose A, Mu F . A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. PLoS One. 2014; 9(2):e87681. PMC: 3928107. DOI: 10.1371/journal.pone.0087681. View

2.
York W, Agravat S, Aoki-Kinoshita K, McBride R, Campbell M, Costello C . MIRAGE: the minimum information required for a glycomics experiment. Glycobiology. 2014; 24(5):402-6. PMC: 3976285. DOI: 10.1093/glycob/cwu018. View

3.
Schulz B, Sloane A, Robinson L, Prasad S, Lindner R, Robinson M . Glycosylation of sputum mucins is altered in cystic fibrosis patients. Glycobiology. 2007; 17(7):698-712. DOI: 10.1093/glycob/cwm036. View

4.
Serisier D, Carroll M, Shute J, Young S . Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum. Respir Res. 2009; 10:63. PMC: 2712464. DOI: 10.1186/1465-9921-10-63. View

5.
Ehre C, Rushton Z, Wang B, Hothem L, Morrison C, Fontana N . An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J Respir Crit Care Med. 2018; 199(2):171-180. PMC: 6353008. DOI: 10.1164/rccm.201802-0245OC. View